drugset / Trial / NCT07422857
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This study is to evaluate the efficacy and safety of \[18F\]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.
Timeline
- Start
- 2026-01-22
- Primary completion
- 2026-12-01
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [18F]APN-1607 | Diagnostic / imaging agent | 5 unknown | Intravenous |
| Subject | [18F]APN-1607 | Diagnostic / imaging agent | 7 unknown | Intravenous |